ClinicalTrials.gg

Program

Modified-release Calcifediol Capsule

Also written as “CTAP101 Capsules”, “CTAP101” and “CTAP101 30 μg capsules”.

Its studies are mostly in Renal Insufficiency, Chronic · Hyperparathyroidism, Secondary · Vitamin D Deficiency · COVID-19 · Breast Neoplasms, led by OPKO Health.

Furthest: phase 3, since Oct 11, 201010 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
OPKO Health101 open or runningphase 3since Oct 11, 2010Apr 23, 2009Oct 2027phase 2 · NCT07494045

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 23, 2009First study: phase 1 study in Renal Insufficiency, ChronicFirst studyNCT00888069 · 28 enrolled · United States
  2. Oct 11, 2010Phase 3 study in Renal Insufficiency, ChronicNCT01219855 · 78 enrolled · United States
  3. Jul 23, 2012Phase 3 study in Renal Insufficiency, ChronicNCT01651000 · 213 enrolled · United States
  4. Oct 6, 2012Phase 3 study in Renal Insufficiency, ChronicNCT01704079 · 216 enrolled · United States
  5. Oct 22, 2014Phase 1 study in Breast NeoplasmsNCT02274623 · 33 enrolled · United States
  6. Oct 31, 2014Phase 3 study in Renal Insufficiency, ChronicNCT02282813 · 298 enrolled
  7. Aug 23, 2018Phase 1 study in Hyperparathyroidism, SecondaryNCT03660800 · 67 enrolled · United States
  8. Sep 15, 2020Phase 2 study in COVID-19NCT04551911 · 171 enrolled · United States
  9. Sep 13, 2022Phase 3 study in Vitamin D DeficiencyNCT05543928 · 2 enrolled · United States
  10. Mar 20, 2026Phase 2 study in Hyperparathyroidism, SecondaryNCT07494045 · 40 planned · United States

Ahead

  1. Oct 2027Primary completion: phase 2 study in Hyperparathyroidism, SecondaryNCT07494045

TargetBeta

VDR →read by rule
“Vitamin D receptor agonist”ChEMBL 37, by rule

Other programs on VDR

ProgramCompanyFurthest phaseStudies
calcipotrieneruleLEO Pharmaphase 439

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07494045Hyperparathyroidism, Secondary · United States2RecruitingOct 202740
NCT05543928Vitamin D Deficiency · United States3TerminatedJun 19, 20242
NCT04551911COVID-19 · United States2CompletedOct 8, 2021171
NCT03660800Hyperparathyroidism, Secondary · United States1CompletedOct 24, 201867
NCT02282813Renal Insufficiency, Chronic3CompletedMay 2015298
NCT02274623Breast Neoplasms · United States1CompletedFeb 27, 201733
NCT01704079Renal Insufficiency, Chronic · United States3CompletedAug 2014216
NCT01651000Renal Insufficiency, Chronic · United States3CompletedJul 2014213
NCT01219855Renal Insufficiency, Chronic · United States3CompletedNov 201178
NCT00888069Renal Insufficiency, Chronic · United States1CompletedNov 200928

How it is read

Names in the registry

  • “CTAP101 Capsules”, 4 entries
  • “CTAP101”, 2 entries
  • “CTAP101 30 μg capsules”, 2 entries
  • “Rayaldee”, 1 entry
  • “Cohort 1 CTAP101 Capsules- 60µg”, 1 entry

Codes read as this program: CTAP101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.